← Leaderboards
Yuri F. Van Der Heijden
Vanderbilt University
$3,583,425
Attributed
$3,583,425
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $627.4K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,583,425 · 2
By mechanism
R01$2,735,126 · 1
K08$848,299 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Neil Osheroff$12,336,075
- Timothy S Blackwell$28,109,454
- Courtney Michelle Campbell$127,627
- Gordon R. Bernard$207,867,283
- Alexandria Oviatt$58,335
Others in their field
Top investigators on “Treatment Outcome”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Judith S. Currier · University Of California Los Angeles$241,389,305
- James Dennis Neaton · Northwestern University$213,587,039
- Gregory H Reaman · National Childhood Cancer Foundation$207,581,079
- Constance Ann Benson · University Of California, San Diego$181,535,584
Research focus
Treatment OutcomeTreatment ProtocolsPharmaceutical PreparationsTreatment DurationResistanceSouth AfricaInsightInjectableMutationMycobacterium TuberculosisPredispositionProvinceResourcesRifampinDrug ResistanceDiagnosisGenesGenotypeIsoniazidLaboratoriesCessation Of LifeMycobacterialDrug Resistance In TuberculosisTuberculosis
Grant awards (12)
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa$348,488
R01 · FY2025 · AI · contact PI
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa$163,148
R01 · FY2025 · AI · contact PI
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa$627,360
R01 · FY2024 · AI · contact PI
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa$373,497
R01 · FY2023 · AI · contact PI
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa$614,798
R01 · FY2022 · AI · contact PI
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa$607,835
R01 · FY2021 · AI · contact PI
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis$175,328
K08 · FY2018 · AI · contact PI
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis$176,321
K08 · FY2017 · AI · contact PI
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis$164,356
K08 · FY2016 · AI · contact PI
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis$105,391
K08 · FY2015 · AI · contact PI
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis$60,115
K08 · FY2015 · AI · contact PI
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis$166,788
K08 · FY2014 · AI · contact PI